RxDoctor Payments Data

Angela McSwain, MD

Neurology · Athens, GANPI 1760462568

Payments from drug & device makers

$557in general payments, 2019–2025

Across 33 payments — averaging $16.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$244
  • AstraZeneca$100
  • Argenx US, Inc.$61
  • Harmony Biosciences LLC$45
  • Amgen$38
  • Johnson & Johnson$25
  • plus $45 from 3 others

What the payments were for

  • Food & beverage$36766%
  • Education$19034%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$557 in reported general payments places this provider in the 35th percentile of 506 neurology providers in Georgia.

See all neurology providers in Georgia

Medicare billing

Part B allowed, 2024
$123,954
Medicare patients
300
Services billed
4,251

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab41$366,875
RytaryCarbidopa/Levodopa51$76,571
Nurtec OdtRimegepant Sulfate40$62,842
QuliptaAtogepant43$47,398
UbrelvyUbrogepant41$41,542
Aimovig AutoinjectorErenumab-Aooe36$29,047
NuedextaDextromethorphan Hbr/Quinidine13$23,259
ReyvowLasmiditan Succinate31$22,467
Emgality PenGalcanezumab-Gnlm25$17,524
Memantine Hcl395$12,860
Rivastigmine56$10,522
NeuproRotigotine12$10,341
EliquisApixaban12$9,918
Carbidopa-LevodopaCarbidopa/Levodopa292$9,005
Gabapentin371$7,506

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieQulipta, Ubrelvy, Savella$244$94,20295 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 506 neurology providers in Georgia.

Other neurology in Athens

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →